Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. ELZONRISď (tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). ELZONRIS is also being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and acute myeloid leukemia (AML). Additional pipeline candidates include: felezonexor (SL-801) (XPO1 inhibitor; Phase 1 in advanced solid tumor patients ongoing), SL-1001 (novel RET kinase inhibitor, IND-enabling studies ongoing), SL-701 (immunotherapeutic; Phase 2 in glioblastoma patients completed), and SL-901 (novel kinase inhibitor; prior abbreviated European Phase 1, IND-enabling studies ongoing). Source
No articles found.
Eiger is a late stage biopharmaceutical company focused on the development and com...
Eiger is a late stage biopharmaceutical company...
PAVmed Inc. is a highly differentiated, multiproduct medical device company employ...
PAVmed Inc. is a highly differentiated, multipr...
Spark Therapeutics, a fully integrated company, strives to challenge the inevitabi...
Spark Therapeutics, a fully integrated company,...
Checkpoint Therapeutics, Inc. (âCheckpointâ) is a clinical-stage, immuno-oncol...
Checkpoint Therapeutics, Inc. (âCheckpointâ...
IVERIC bio is a gene therapy focused company developing innovative treatments for ...
IVERIC bio is a gene therapy focused company de...
RB is the global leading consumer health, hygiene and home company. Driven by a pu...
RB is the global leading consumer health, hygie...
Headquartered in Mountain View, California, IGM Biosciences is a biotechnology com...
Headquartered in Mountain View, California, IGM...
Join the National Investor Network and get the latest information with your interests in mind.